- Home
- IGMS vs LMNR Comparison
IGMS vs LMNR Comparison
Compare IGMS & LMNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- LMNR
- Stock Information
- Founded
- IGMS 1993
- LMNR 1893
- Country
- IGMS United States
- LMNR United States
- Employees
- IGMS N/A
- LMNR N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- LMNR Farming/Seeds/Milling
- Sector
- IGMS Health Care
- LMNR Consumer Staples
- Exchange
- IGMS Nasdaq
- LMNR Nasdaq
- Market Cap
- IGMS 528.6M
- LMNR 486.1M
- IPO Year
- IGMS 2019
- LMNR N/A
- Fundamental
- Price
- IGMS $7.48
- LMNR $26.68
- Analyst Decision
- IGMS Buy
- LMNR Buy
- Analyst Count
- IGMS 8
- LMNR 2
- Target Price
- IGMS $16.25
- LMNR $24.00
- AVG Volume (30 Days)
- IGMS 213.0K
- LMNR 36.6K
- Earning Date
- IGMS 11-08-2024
- LMNR 12-23-2024
- Dividend Yield
- IGMS N/A
- LMNR 1.12%
- EPS Growth
- IGMS N/A
- LMNR N/A
- EPS
- IGMS N/A
- LMNR 0.29
- Revenue
- IGMS $2,918,000.00
- LMNR $189,075,000.00
- Revenue This Year
- IGMS $386.95
- LMNR $7.75
- Revenue Next Year
- IGMS N/A
- LMNR $16.50
- P/E Ratio
- IGMS N/A
- LMNR $91.28
- Revenue Growth
- IGMS 57.64
- LMNR 6.15
- 52 Week Low
- IGMS $6.17
- LMNR $17.37
- 52 Week High
- IGMS $22.50
- LMNR $29.22
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- LMNR 46.16
- Support Level
- IGMS $7.00
- LMNR $26.39
- Resistance Level
- IGMS $10.80
- LMNR $27.42
- Average True Range (ATR)
- IGMS 1.02
- LMNR 0.78
- MACD
- IGMS -0.10
- LMNR -0.08
- Stochastic Oscillator
- IGMS 10.39
- LMNR 29.39
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About LMNR Limoneira Co
Limoneira Co is an agribusiness company. The company's operating segments include Fresh Lemons; Lemon Packing; Avocados and Other Agribusiness. It generates maximum revenue from the Fresh Lemons segment.